[CAS NO. 1026987-94-9] DUPA(OtBu)-OH
PRODUCTS SPECIFICATIONS [1026987-94-9]
DESCRIPTION [1026987-94-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 488.57 |
| Molecular Formula | C23H40N2O9 |
| SMILES | O=C(OC(C)(C)C)CC[C@@H](C(OC(C)(C)C)=O)NC(N[C@H](C(OC(C)(C)C)=O)CCC(O)=O)=O |
1 Publications Citing Use of MCE
Summary
DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer .
In Vitro
DUPA(OtBu)-OH (DUPA precursor 17) is a 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid (DUPA) reagent [1] . The targeting ligand DUPA enhances the transport capability and selectivity of Paclitaxel (PTX) to tumor cells via prostate-specific membrane antigen (PSMA) mediated endocytosis. Besides, DUPA is conjugated with PTX via a disulfide bond, which facilitates the rapid and differential drug release in tumor cells [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
DUPA-targeted Docetaxel (DTX) conjugate with longer spacer has no toxicity in major organs of treated mice [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 125 mg/mL ( 255.85 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0468 mL | 10.2339 mL | 20.4679 mL |
| 5 mM | 0.4094 mL | 2.0468 mL | 4.0936 mL |
| 10 mM | 0.2047 mL | 1.0234 mL | 2.0468 mL |
References
- [1] Roy J, et al. DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selectiveprostate cancer cell targeting. J Med Chem. 2015 Apr 9;58(7):3094-103.
- [2] Lv Q, et al. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate. Mol Pharm. 2018 May 7;15(5):1842-1852.
- [3] Peng ZH, et al. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specificmembrane antigen expressing prostate cancer. J Drug Target. 2013 Dec;21(10):968-80.